

General synthetic approach to 2-phenolic adenine derivatives

Carla Correia, M. Alice Carvalho,* Ashly Rocha and M. Fernanda Proença.

Departamento de Química, Universidade do Minho, Campus de Gualtar, 4710-057 Braga, Portugal

Fax: +351 253 678 983

E-mail: mac@quimica.uminho.pt

Received: The date will be inserted once the manuscript is accepted.

Dedication - If you wish to insert a short dedication please overwrite this text, otherwise delete the paragraph.

Abstract: A simple and general “one pot” procedure for the synthesis of 2,9-diarylpurines with one or multiple hydroxyl groups in the 2-aryl unit is described, from the reaction of 5-amino-4-amidinoimidazoles with phenolic aldehydes.

Key words: nucleobases, phenols, condensations, aldehydes, ring closure.

Purines have attracted attention of the scientific community mainly due to their biological activity.¹ During the last decade, purine derivatives were identified as a promising new class of antitubercular agents. The research was focused on the synthesis of nucleoside analogues as siderophore biosynthesis inhibitors,² and on non nucleosides.³ In the non nucleoside series, purines having an aryl, a small alkyl or a proton on 9-N were essentially inactive, whereas 9-benzyl-6-(2-furyl)purines,^{3b,h,j} 9-sulfonyl-6-mercaptapurines or 6-alkylthiopurines^{3e,k} were highly potent. In addition, we recently described the first example of 2,9-diarylpurines (Figure 1) active against *Mycobacterium tuberculosis*.⁴ The results from biological evaluation showed that the potency of the compounds depends on the substituents in 9-N, 2-C and 6-C of the purine core. The presence of a 4-tolyl group in 9-N and a 3-hydroxyphenyl or a 4-hydroxyphenyl substituent in 2-C combined with a secondary amine in 6-C proved to be important features for activity (Figure 1) but a clear structure-activity correlation pattern could not be identified.⁴




Figure 1 Hit compounds active on *Mycobacterium tuberculosis*

A number of synthetic methods were developed to incorporate functional groups in the purine core, but costly reagents are usually required.^{5a,b} In our research group purine derivatives have been obtained by a simple and inexpensive synthetic approach that uses the versatile reactivity of a substituted imidazole.^{4,5c-1}

The 6-amino-2,9-diarylpurines (Figure 1) are a new promising scaffold active against *Mycobacterium tuberculosis* and the presence of hydroxyl groups in the aryl subunit in 2-C was considered an important


feature for activity. The microorganism needs iron for the biochemical processes and multiple hydroxyl groups in the phenolic subunit could enhance the complexation with the metal. This perception prompted us to develop a new synthetic approach that would allow the efficient synthesis of purines **6** (table 1) having a phenolic subunit in 2-C with two and three hydroxyl substituents. The previous method only allowed the introduction of phenolic units with one hydroxyl group as the reaction with polyphenolic aldehydes, performed in basic medium, was very slow (8-54 days) and extensive degradation occurred.⁴

Herein we describe a new and general synthetic approach for 6-amino-9-aryl-2-hydroxy or 2-(polyhydroxyphenyl)purines **6** using imidazole **1**, phenolic aldehydes **2** and a cascade of acid and basic catalysis.

When compound **1a** (Scheme 1) was combined with 3,4,5-trihydroxybenzaldehyde **2a**, in ethanol at 0 °C, using trifluoroacetic acid as catalyst, the starting materials were dissolved and a new white solid precipitated after 5 minutes. This compound was identified as the trifluoroacetate salt of starting material **3**. When the reaction was repeated using 2.0 equiv of the acid, a yellow solid precipitated after 4 hours and was identified as **4a**⁶ (Scheme 1).

When imidazole **1b** was reacted with monohydroxy or dihydroxyphenylaldehydes **2b** or **2c**, at 6 °C, no solid precipitated from the initial yellow solutions. When the TLC showed the absence of imines **4**, off white solids were isolated and identified as dihydropurines **5a,b**^{7a} (Scheme 1). Dihydropurine **5c** was also isolated in the reaction of imidazole **1a** with 3,4,5-trihydroxyphenylaldehyde **2a** when the reaction was carried out at room temperature (Scheme 1). The imine **4a** also evolved to the dihydropurine **5c**^{7b} after 10 days in ethanolic solution at 8 °C (Scheme 1).

The pure imine **4a** showed a single spot on TLC however, by ¹H NMR, the spectrum obtained in DMSO solution showed signals consistent with the presence of two compounds in a 7:3 molar ratio. The major compound was identified as **4a** (70%) and the minor compound as the dihydropurine **5c** (30%). These results suggested that, in DMSO solution, the imine **4a** was cyclizing to the dihydropurine **5c**. In order to confirm this result a new ¹H NMR spectrum was registered after 2 hours. The spectrum showed once again a mixture of **4a** and **5c** but in a 1:9 molar



Scheme 1 Reactions of imidazoles **1** with phenolic aldehydes **2** in acidic medium

ratio and this ratio did not change after one week, at room temperature. When the solution was heated in the NMR tube at 60 °C during 10 minutes a mixture of **4a** and **5c** was still present, however new signals were observed in the spectrum, assigned to purine **6i**, and to the imidazole **1a** and aldehyde **2a**, the starting reagents. The hydrolysis of the imine **4a** was also

observed by ¹H NMR in an acidified solution of **4a** in DMSO-d₆. These results indicate that in DMSO solution, at room temperature, the imine **4a** evolves rapidly to the dihydropurine **5c** leading to an equilibrium mixture. Under heating, compound **5c** evolves to generate the purine **6i**. However, in acid

Table 1 Synthesis of purines **6**

Imidazole (1)		Aldehyde (2)	Reaction conditions	product	Yield (%)
R ¹	R ²	R ³			
1b	4-MeC ₆ H ₄	2b 2-HOC ₆ H ₄	i) a) 1b (0.12 g), 2b (1.1 eq.), EtOH, TFA (1.3 eq), 11°C, 1 day b) DMSO (0.2 mL), Et ₃ N(10 eq), 40°C, 2 days	6a	73
1b	4-MeC ₆ H ₄	2d 3-HOC ₆ H ₄	i) a) 1b (0.12 g), 2d (1.1 eq.), EtOH, TFA (1.3 eq), 11°C, 7 days b) DMSO (0.2 mL), Et ₃ N(10 eq), 40°C, 2 days	6b	79
1b	4-MeC ₆ H ₄	2e 4-HOC ₆ H ₄	i) a) 1b (0.13 g), 2e (1.1 eq.), EtOH, TFA (1.3 eq), 11°C, 1 day b) DMSO (0.2 mL), Et ₃ N(10 eq), 40°C, 2 days	6c	78
1b	4-MeC ₆ H ₄	2f 2,3-(HO) ₂ C ₆ H ₃	i) a) 1b (0.17 g), 2f (1.1 eq.), EtOH, TFA (2.0 eq), r.t., 30 min b) DMSO, EtOH, Et ₃ N(10 eq), 40°C, 6 days	6d	88
1b	4-MeC ₆ H ₄	2c 3,4-(HO) ₂ C ₆ H ₃	i) a) 1b (0.12 g), 2c (1.1 eq.), EtOH, TFA (1.3 eq), 11°C, 1 day b) DMSO, Et ₃ N(10 eq), 40°C, 4 days	6e	58
1b	4-MeC ₆ H ₄	2g 2,3,4-(HO) ₃ C ₆ H ₂	i) a) 1b (0.30 g), 2g (1.1 eq.), EtOH, TFA (1.3 eq), r.t., 1 day b) DMSO, Et ₃ N(10 eq), 40°C, 6 days	6f	59
1b	4-MeC ₆ H ₄	2a 3,4,5-(HO) ₃ C ₆ H ₂	i) a) 1b (0.28 g), 2a (1.1 eq.), EtOH, TFA (1.3 eq), r.t., 6 days b) DMSO, Et ₃ N(10 eq), 40°C, 1 day	6g	50
1a	4-MeC ₆ H ₄	2c 3,4-(HO) ₂ C ₆ H ₃	i) a) 1a (0.21 g), 2c (1.1 eq.), EtOH, TFA (1.5 eq), r.t., 6 days b) DMSO, Et ₃ N(10 eq), 40°C, 4 days	6h	57
1a	4-MeC ₆ H ₄	2a 3,4,5-(HO) ₃ C ₆ H ₂	i) a) 1a (0.21 g), 2a (1.1 eq.), EtOH, TFA (1.5 eq), r.t., 10 days b) DMSO, Et ₃ N(10 eq), 80°C, 1 day	6i	57
1c	4-MeC ₆ H ₄	2a 3,4,5-(HO) ₃ C ₆ H ₂	i) a) 1c (0.16 g), 2a (1.1 eq.), EtOH, TFA (1.3 eq), r.t., 5 days b) DMSO, Et ₃ N(10 eq), 80°C, 1 day	6j	67
1c	4-MeC ₆ H ₄	2g 2,3,4-(HO) ₃ C ₆ H ₂	i) a) 1c (0.11 g), 2g (1.1 eq.), EtOH, TFA (1.3 eq), r.t., 4 days b) DMSO, Et ₃ N(10 eq), 40°C, 5 days	6k	60

solution, hydrolysis of the imine regenerates the starting materials **1a** and **2a**.

The dihydropurine **5c** was also solubilised in DMSO-*d*₆ and the ¹H NMR spectrum, acquired after 5 minutes, showed that **5c** was the only product present in solution. However, after the addition of triethylamine and heating at 80 °C for 20 hours only purine **6i** was present in solution.

Considering that the reaction of imidazoles **1** with aldehydes **2**, in ethanol in the presence of 1.3-2 equiv of TFA led to imines **4** and dihydropurines **5**, and that compounds **4** and **5** in DMSO solution, under heating, and in the presence of triethylamine generated the desired purine **6**, a new “one pot” synthetic procedure to generate purines **6**⁸ was designed, starting from imidazoles **1** and aldehydes **2**. The reaction was initially carried out in ethanol and acid (1.3-2 equiv) until total consumption of the starting materials (by TLC). The solvent was then removed in the rotary evaporator and the reactions proceeded in DMSO and base, with heating.

These experimental conditions were applied to the reaction of imidazoles **1a-c** with aldehydes **2a-g**, having one, two or three hydroxyl groups. The purines **6a-k** were obtained directly from the reaction mixture after 2-10 days (Table 1). When degradation was observed, the pure products were isolated in lower yields after dry flash chromatography (compounds **6e-h**).

In summary this work describes a new versatile and simple “one-pot” method to synthesize 6-amino-9-substituted-2-hydroxy or 2-(polyhydroxyphenyl)purines **6** starting from imidazoles **1** and phenolic aldehydes **2**. The formation of the imine intermediate, is favoured in ethanol using acid catalysis, however the cyclization and oxidation, to generate the purine core, is favoured in dimethylsulfoxide, under heating, using base catalysis.

Acknowledgements

The NMR spectrometer (Bruker 400 Avance III) is part of the National NMR Network, supported with funds from Fundação para a Ciência e a Tecnologia (FCT). The authors gratefully acknowledge the financial support by F.C.T. (project n°F-COMP-01-0124-FEDER-022716 (ref. FCT PEst-QUI/UI0686/2011) FEDER-COMPETE, FCT-Portugal and the PhD grant to C. Correia (SFRH/BD/22270/2005).

References and notes

- (1) Legraverend, M.; Grierson, D. S. *Bioorg. Med. Chem.* **2006**, *14*, 3987.
- (2) a) Gupte, A.; Boshoff, H. I.; Wilson, D. J.; Neres, J.; Labello, N. P.; Somu, R. V.; Xing, C.; Barry III, C. E.; Aldrich, C. C. *J. Med. Chem.*, **2008**, *51* (23), 7495; b) Neres, J.; Labello, N. P.; Somu, R. V.; Boshoff, H. I.; Wilson, D. J.; Vannada, J.; Chen L.; Barry III, C. E.; Bennett, E. M.; Aldrich, C. C. *J. Med. Chem.*, **2008**, *51* (17), 5349; c) Long, M. C.; Shaddix, S. C.; Moukha-Chafiq, O.; Maddry, J. A.; Nagy, L.; Parker, W. B. *Biochem. Pharmacol.* **2008**, *75*, 1588; d) Bissert, P.; Thielges, S.; Bourg, S.; Miethke, M.; Marahiel, M. A.; Eustachea, J. *Tetrahedron Letters* **2007**, *48*, 6080; e) Qiao, C.; Gupte, A.; Boshoff, H. I.; Wilson, D. J.; Bennett, E. M.; Somu, R. V.; Barry, C. E.; Aldrich, C. C. *J. Med. Chem.*, **2007**, *50* (24), 6080; f) Rai, D.; Johar, M.; Srivastav, N. C.; Manning, T.; Agrawal, B.; Kunimoto, D. Y.; Kumar, R. *J. Med. Chem.*, **2007**, *50* (19), 4766; g) Qiao, C.; Wilson, D. J.; Bennett, E. M.; Aldrich, C. C. *J. Am. Chem. Soc.*, **2007**, *129* (20), 6350; h) Vannada, J.; Bennett, E. M.; Wilson, D. J.; Boshoff, H. I.; Barry, C. E.; Aldrich, C. C. *Org. Lett.*, **2006**, *8* (21), 4707; i) Somu, R. V.; Wilson, D. J.; Bennett, E. M.; Boshoff, H. I.; Celia, L.; Beck, B. J.; Barry, C. E.; Aldrich, C. C. *J. Med. Chem.*, **2006**, *49* (26), 7623; j) Bennett, E. M.; Barry, C. E.; Aldrich, C. C. *J. Med. Chem.*, **2006**, *49* (1), 31.
- (3) a) Bakkestuen, A. K.; Gundersen, L.-L.; Utenova, B. T. *J. Med. Chem.* **2005**, *48*, 2710; b) Braendvang, M.; Gundersen, L.-L. *Bioorg. Med. Chem.* **2007**, *15*, 7144; c) Braendvang, M.; Gundersen, L.-L. *Bioorg. Med. Chem.* **2005**, *13*, 6360; d) Bakkestuen, A. K.; Gundersen, L.-L.; Petersen, D.; Utenova, B. T.; Vik, A. *Org. Biomol. Chem.* **2005**, *3*, 1025; e) Pathak, A. K.; Pathak, V.; Seitz, L. E.; Suling, W. J.; Reynolds, R. C. *J. Med. Chem.*, **2004**, *47* (1), 273; f) Barrow, E. W.; Westbrook, L.; Bansal, N.; Suling, W. J.; Maddry, J. A.; Parker, W. B.; Barrow, W. W. *J. Antimicrob. Chemother.*, **2003**, *52*, 801; g) Andersen, G.; Gundersen, L.-L.; Nissen-Meyer, J.; Rise, F.; Spilsberg, B. *Bioorg. Med. Chem. Lett.*, **2002**, *12*, 567; h) Gundersen, L.-L.; Nissen-Meyer, J.; Spilsberg, B. *J. Med. Chem.* **2002**, *45*, 1383; i) Scozzafava, A.; Mastrolorenzo, A.; Supuran, C. T. *Bioorg. Med. Chem Lett.* **2001**, *11*, 1675; j) Bakkestuen, A. K.; Gundersen, L.-L.; Langli, G.; Liu, F.; Nolsoe, J. M. *J. Bioorg. Med. Chem Lett.* **2000**, *10*, 1207; k) Scozzafava, A.; Mastrolorenzo, A.; Supuran, C. T.; *Bioorg. Med. Chem. Lett.* **2001**, *11*, 1675.
- (4) Correia, C.; Carvalho, M. A.; Proença, M. F. *Tetrahedron*, **2009**, *65*, 6903.
- (5) a) For a recent review see Legraverend, M. *Tetrahedron* **2008**, *64*, 8585; b) Ibrahim, N.; Legraverend, M. *J. Org. Chem.*, **2009**, *74* (1), 463; c) Alves, M. J.; Booth, B. L.; Freitas, A. P.; Proença, M. F. *J. Chem. Soc. Perkin Trans. 1* **1992**, 913; d) Booth, B. L.; Dias, A. M.; Proença, M. F. *J. Chem. Soc. Perkin Trans. 1* **1992**, 2119; e) Alves, M. J.; Booth, B. L.; Proença, M. F. *J. Heterocycl. Chem.* **1994**, *31*, 345; f) Booth, B. L.; Coster, R. D.; Proença, M. F. *Synthesis* **1988**, 389; g) Alves, M. J.; Booth, B. L.; Carvalho, M. A.; Pritchard, R. G.; Proença, M. F. *J. Heterocycl. Chem.* **1997**, *34*, 739; h) Al-Azmi, A.; Booth, B. L.; Carpenter, R. A.; Carvalho, M. A.; Marrelec, E.; Pritchard, R. G.; Proença, M. F. *J. Chem. Soc. Perkin Trans. 1* **2001**, 2532; i) Booth, B. L.; Cabral, I. M.; Dias, A. M.; Freitas, A. P.; Matos-Beja, A. M.; Proença, M. F.; Ramos-Silva, M. *J. Chem. Soc. Perkin Trans. 1* **2001**, 1241; j) Carvalho, M. A.; Esteves, T. M.; Proença, M. F.; Booth, B. L. *Org. Biomol. Chem.* **2004**, *2*, 1019; k) Carvalho, M. A.; Álvares, Y.; Zaki, M. E.; Proença, M. F.; Booth, B. L. *Org. Biomol. Chem.* **2004**, *2*, 2340; l) Alves, M. J.; Carvalho, M. A.; Carvalho, S.; Dias, A. M.; Fernandes, F. H.; Proença, M. F. *Eur. J. Org. Chem.* **2007**, 4881.
- (6) **Procedure for the synthesis of imine 4a (Scheme 1):** To a stirred suspension of imidazole **1a** (0.14 g, 0.49 mmol) in ethanol (0.4 mL), 1.1 equiv of aldehyde **2a** (0.09 g, 1.1 equiv) and 2 equiv of TFA (75 µL) were

added, at 0 °C. A yellow solution developed and a yellow solid started to precipitate after 25 minutes. When the TLC indicated the absence of starting material (4 h), ethanol was added (0.8 mL) and the yellow solid was filtered. The solid was washed with ethanol and diethyl ether and identified as compound **4a** (0.22 g, 0.40 mmol, 82 %). mp 124 – 126 °C. IR (Nujol mull): 3498, 3352, 3210, 1665, 1626, 1604, 1586, 1521 cm⁻¹. ¹H NMR (300 MHz, DMSO-*d*6): δ = 1.62 (s, 6H, CH₂), 2.37 (s, 3H, CH₃), 3.58 (br s, 4H, CH₂), 6.82 (s, 2H, Ar-H), 7.30–7.45 (m, 4H, Ar-H), 8.17 (s, 2H, 2-H, N=CH), 8.80–9.60 (m, 5H, NH, HO, D₂O exchangeable). Anal. calcd for C₂₃H₂₅N₅O₃·CF₃COOH·H₂O: C, 54.44; H, 5.08; N, 12.70. Found: C, 54.68; H, 5.41; N, 12.45.

- (7) **Procedure for the synthesis of dihydropurines 5c (Scheme 1):** Method i) Aldehyde **2a** (0.07 g, 1.0 equiv) and TFA (40 μL, 1.3 equiv) were added to a stirred suspension of imidazole **1a** (0.11 g, 0.40 mmol) in ethanol (2.0 mL), at room temperature. The yellow solution became light yellow and when TLC showed the absence of imine **4** (5 days), the solution was concentrated in the rotary evaporator. The off-white solid was filtered, washed with ethanol and diethyl ether and identified as compound **5c** (0.09 g, 0.16 mmol, 41 %). Method ii) A yellow ethanolic solution of **4a** (0.09 g, 0.16 mmol) was stirred at 8 °C until TLC showed the absence of starting material (10 days). The solution was concentrated in the rotary evaporator leading to an off-white solid that was filtered and washed with diethyl ether and identified as compound **5c** (0.08 g, 0.15 mmol, 91 %). mp 218–220 °C. IR (Nujol mull): 3535, 3202, 1679, 1613, 1530 cm⁻¹. ¹H NMR (300 MHz, DMSO-*d*6): δ = 1.69 (s, 6H, CH₂), 2.39 (s, 3H, CH₃), 3.70 (m, 4H, CH₂), 5.71 (t, 1H, *J* = 4.8 Hz, 2-H), 6.28 (s, 2H, Ar-H), 7.40–7.46 (m, 4H, Ar-H), 7.88 (s, 1H, 8-H), 8.07 (d, 1H, *J* = 4.8 Hz, NH, D₂O exchangeable), 8.23 (br s, 1H, HO, D₂O exchangeable), 8.88 (d, 1H, *J* = 4.8 Hz, NH, D₂O exchangeable), 8.99 (s, 2H, HO, D₂O

exchangeable). ¹³C NMR (75 MHz, DMSO-*d*6): δ = 20.62 (CH₃), 23.32, 25.80, 48.82, 64.77 (2-C), 105.12, 110.60, 124.14, 129.16, 130.32, 130.88, 133.39, 135.14 (8-C), 138.65, 145.73, 145.84, 150.00. Anal. calcd for C₂₃H₂₅N₅O₃·CF₃COOH·2.1H₂O: C, 52.56; H, 5.29; N, 12.26. Found: C, 52.55; H, 5.10; N, 12.07.

- (8) **Procedure for the synthesis of purine 6f (Table 1):** Aldehyde **2g** (0.18 g, 1.1 equiv) and TFA (166 μL, 1.3 equiv) were added to a stirred suspension of imidazole **1b** (0.30 g, 1.08 mmol) in ethanol (0.3 mL), at room temperature during 1 day. Then, the solvent was removed in the rotary evaporator, and DMSO (0.3 mL) was added to the crude solid followed by triethylamine (1.35 mL, 10 equiv) and the reaction was stirred at 40 °C during 6 days. Addition of water and cooling for 10 minutes led to a brown solid that was filtered and washed with water and diethyl ether (0.42 g). The brown solid was purified by dry flash chromatography on silica gel using 500 mL of diethyl ether as eluent to give an off-white solid identified as **6f** (0.25 g, 0.60 mmol, 59 %). mp > 300 °C. IR (Nujol mull): 3550, 3465, 3337, 3101, 1637, 1624, 1581, 1528 cm⁻¹. ¹H NMR (300 MHz, DMSO-*d*6): δ = 2.41 (s, 3H, CH₃), 3.85 (s, 4H, CH₂), 4.30 (br s, 4H, CH₂), 6.36 (d, 1H, *J* = 9.0 Hz, Ar-H), 7.43 (d, 2H, *J* = 8.4, Ar-H), 7.64 (d, 2H, *J* = 8.7 Hz, Ar-H), 7.68 (d, 1H, *J* = 9.0 Hz, Ar-H), 8.24 (br s, 1H, HO, D₂O exchangeable), 8.45 (s, 1H, 8-H), 9.16 (br s, 1H, HO, D₂O exchangeable), 13.45 (s, 1H, HO, D₂O exchangeable). ¹³C NMR (75 MHz, DMSO-*d*6): δ = 20.64 (CH₃), 45.52, 66.13, 107.05, 111.53, 117.57, 119.45, 123.82, 130.17, 131.99, 132.69, 137.77, 139.18 (8-C), 148.54, 148.93, 149.36, 152.66, 158.86 (2-C). Anal. calcd for C₂₂H₂₁N₅O₄·0.5H₂O: C, 61.68; H, 5.14; N, 16.36. Found: C, 61.75; H, 5.06; N, 16.20.